# Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone

> **NCT01849094** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Alfred** · enrollment: 9 (actual)

## Conditions studied

- Healthy
- Heart Failure

## Interventions

- **DRUG:** Milrinone 6mg
- **DRUG:** milrinone 10mg ER
- **DRUG:** milrinone 14mg

## Key facts

- **NCT ID:** NCT01849094
- **Lead sponsor:** The Alfred
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849094, "Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01849094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*